Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

(2016) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

(2016) Jun Wang et al.   OncoTargets and Therapy

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

CD271 is expressed in melanomas with more aggressive behaviour, with correlation of characteristic morphology byin vivoreflectance confocal microscopy

(2015) F. Beretti et al.   BRITISH JOURNAL OF DERMATOLOGY

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

(2015) Jarushka Naidoo et al.   CANCER

Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations

(2015) K. Rycaj et al.   CANCER RESEARCH

Clonal evolution and tumor-initiating cells: New dimensions in cancer patient treatment

(2015) Anthony J. Apostoli et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

(2015) Hyo-eun C Bhang et al.   NATURE MEDICINE

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Persisters unmasked

(2015) D. W. Holden   SCIENCE

Cancer stem cells, cancer cell plasticity and radiation therapy

(2015) Erina Vlashi et al.   SEMINARS IN CANCER BIOLOGY

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

Cancer stem cell plasticity and tumor hierarchy

(2015) Marina Carla Cabrera   World Journal of Stem Cells

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

(2014) Youngjoo Lee et al.   CANCER

A stress-induced early innate response causes multidrug tolerance in melanoma

(2014) D Ravindran Menon et al.   ONCOGENE

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity

(2013) Christine L. Chaffer et al.   CELL

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Rethinking the war on cancer

(2013) Douglas Hanahan   LANCET

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer

(2012) Lara K. Boyd et al.   GENES CHROMOSOMES & CANCER

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor

(2012) Amélie Clémentine Seghers et al.   MELANOMA RESEARCH

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

(2011) J Lin et al.   BRITISH JOURNAL OF CANCER

Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells

(2011) Piyush B. Gupta et al.   CELL

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

(2011) C. L. Chaffer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized

(2010) Elsa Quintana et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution

(2009) Mark Shackleton et al.   CELL

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH